» Articles » PMID: 27270328

MC1R is Dispensable for the Proteinuria Reducing and Glomerular Protective Effect of Melanocortin Therapy

Overview
Journal Sci Rep
Specialty Science
Date 2016 Jun 9
PMID 27270328
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Melanocortin therapy by using adrenocorticotropic hormone (ACTH) or non-steroidogenic melanocortin peptides attenuates proteinuria and glomerular injury in experimental glomerular diseases and induces remission of nephrotic syndrome in patients with diverse glomerulopathies, even those resistant to steroids. The underlying mechanism remains elusive, but the role of melanocortin 1 receptor (MC1R) has been implicated and was examined here. Four patients with congenital red hair color and nephrotic syndrome caused by idiopathic membranous nephropathy or focal segmental glomerulosclerosis were confirmed by gene sequencing to bear dominant-negative MC1R mutations. Despite prior corticosteroid resistance, all patients responded to ACTH monotherapy and ultimately achieved clinical remission, inferring a steroidogenic-independent and MC1R-dispensable anti-proteinuric effect of melanocortin signaling. In confirmatory animal studies, the protective effect of [Nle(4), D-Phe(7)]-α-melanocyte stimulating hormone (NDP-MSH), a potent non-steroidogenic pan-melanocortin receptor agonist, on the lipopolysaccharide elicited podocytopathy was completely preserved in MC1R-null mice, marked by reduced albuminuria and diminished histologic signs of podocyte injury. Moreover, in complementary in vitro studies, NDP-MSH attenuated the lipopolysaccharide elicited apoptosis, hypermotility and impairment of filtration barrier function equally in primary podocytes derived from MC1R-null and wild-type mice. Collectively, our findings suggest that melanocortin therapy confers a proteinuria reducing and podoprotective effect in proteinuric glomerulopathies via MC1R-independent mechanisms.

Citing Articles

Hematopoietic-specific melanocortin 1 receptor signaling protects against nephrotoxic serum nephritis and mediates the beneficial effect of melanocortin therapy.

Guan X, Chen B, Malhotra D, Gohara A, Dworkin L, Gong R Kidney Int. 2022; 103(2):331-342.

PMID: 36374665 PMC: 10431720. DOI: 10.1016/j.kint.2022.09.025.


Pharmacological Melanocortin 5 Receptor Activation Attenuates Glomerular Injury and Proteinuria in Rats With Puromycin Aminonucleoside Nephrosis.

Chen B, Alam Z, Ge Y, Dworkin L, Gong R Front Physiol. 2022; 13:887641.

PMID: 35721571 PMC: 9198460. DOI: 10.3389/fphys.2022.887641.


Therapies for Membranous Nephropathy: A Tale From the Old and New Millennia.

Scolari F, Alberici F, Mescia F, Delbarba E, Trujillo H, Praga M Front Immunol. 2022; 13:789713.

PMID: 35300332 PMC: 8921478. DOI: 10.3389/fimmu.2022.789713.


Melanocortin System in Kidney Homeostasis and Disease: Novel Therapeutic Opportunities.

Chang M, Chen B, Shaffner J, Dworkin L, Gong R Front Physiol. 2021; 12:651236.

PMID: 33716796 PMC: 7943476. DOI: 10.3389/fphys.2021.651236.


Therapeutic Options for Recurrence of Primary Focal Segmental Glomerulonephritis (FSGS) in the Renal Allograft: Single-Center Experience.

Vallianou K, Marinaki S, Skalioti C, Lionaki S, Darema M, Melexopoulou C J Clin Med. 2021; 10(3).

PMID: 33498160 PMC: 7863737. DOI: 10.3390/jcm10030373.


References
1.
Greenbaum L, Benndorf R, Smoyer W . Childhood nephrotic syndrome--current and future therapies. Nat Rev Nephrol. 2012; 8(8):445-58. DOI: 10.1038/nrneph.2012.115. View

2.
Muceniece R, Zvejniece L, Liepinsh E, Kirjanova O, Baumane L, Petrovska R . The MC3 receptor binding affinity of melanocortins correlates with the nitric oxide production inhibition in mice brain inflammation model. Peptides. 2006; 27(6):1443-50. DOI: 10.1016/j.peptides.2005.12.002. View

3.
Berg A, Nilsson-Ehle P, Arnadottir M . Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int. 1999; 56(4):1534-43. DOI: 10.1046/j.1523-1755.1999.00675.x. View

4.
Rouster-Stevens K, Gursahaney A, Ngai K, Daru J, Pachman L . Pharmacokinetic study of oral prednisolone compared with intravenous methylprednisolone in patients with juvenile dermatomyositis. Arthritis Rheum. 2008; 59(2):222-6. PMC: 2852143. DOI: 10.1002/art.23341. View

5.
Elvin J, Buvall L, Lindskog Jonsson A, Granqvist A, Lassen E, Bergwall L . Melanocortin 1 receptor agonist protects podocytes through catalase and RhoA activation. Am J Physiol Renal Physiol. 2016; 310(9):F846-56. DOI: 10.1152/ajprenal.00231.2015. View